

NEW OPTIONS IN HCV THERAPY:

UPDATE
FROM
AASLD
2014



School of Medicine
and Public Health
UNIVERSITY OF WISCONSIN-MADISON



L.I.F.E.R.
LIVER INSTITUTE
FOR EDUCATION
AND RESEARCH

NEW OPTIONS IN HCV THERAPY:

UPDATE
FROM
AASLD
2014

Wednesday, January 21, 2015
Landmarc Restaurant, New York, NY

Ira Jacobson, MD

Chief of the Division of Gastroenterology and Hepatology
Vincent Astor Distinguished Professor of Medicine
Medical Director, Center for the Study of Hepatitis C
Weill Medical College of Cornell University

Agenda

- 6:15 – 6:30 PM Registration and Pre-Assessment
- 6:30 – 6:50 PM Case 1: Liver Failure
- 6:50 – 7:00 PM Discussion
- 7:00 – 7:20 PM Case 2: Cirrhosis
- 7:20 – 7:30 PM Discussion
- 7:30 – 7:50 PM Case 3: Genotype 1 Naive
- 7:50 – 8:00 PM Discussion
- 8:00 – 8:20 PM Case 4: Genotype 3
- 8:20 – 8:30 PM Discussion
- 8:30 – 8:45 PM Post-Assessment

Learning Objectives

As a result of this educational activity, participants will be able to:

1. Delineate which subgroups of patients with HCV infection are likely to benefit from HCV therapy that includes a direct antiviral
2. Implement cost-effective procedures to stage liver disease in patients with HCV infection, before and during antiviral treatment
3. Select the best therapy for HCV patients with specific disease characteristics using evidence-based data
4. List common adverse events associated with HCV therapy that includes a direct antiviral
5. Discuss which HCV therapies may be appropriate for pre- and post- liver transplant patients

Disclosures

Name	Role	Financial Relationship Disclosures
Ira Jacobson, MD	Content Developer, Presenter	AbbVie, Achillion, Alnylam, Bristol-Myers Squibb, Enanta, Genentech, Gilead, Janssen, Merck (Consultant); Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Merck (Independent Contractor/Researcher); Abbvie, Bristol Myers Squibb, Genentech, Gilead, Janssen (Teacher/Speaker)
Nezam Afdhal, MD	Content Developer	AbbVie, Achillion, Boehringer-Ingelheim, Echosens, Gilead Sciences, Glaxosmithkline, Janssen, Kadmon, Ligand, Medgenex, Inc, Merck, Novartis, Springbank, Vertex Pharmaceuticals Inc. (Consultant); AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, Vertex Pharmaceuticals Inc. (Principal Investigator (Pi)); Springbank (Stockholder Or Other Ownership Interest Holder)
Jane Henderson	Planner	No relevant financial relationships to disclose
Danielle Hepting	CME Staff	No relevant financial relationships to disclose
Leslie Jacus	Planner	No relevant financial relationships to disclose
Donna McMullen	Planner	No relevant financial relationships to disclose
Adnan Said, MD	Content Reviewer	No relevant financial relationships to disclose

Meeting Materials

- Pre-Test
- Brochure
- Disclosures
- CME Credit and Slides
- Notes pages
- Post-Test

NEW OPTIONS IN HCV THERAPY:

UPDATE
FROM
AASLD
2014